Good post ruster. The ASX are diluting anything related to COVID and to be fair I’m happy that’s the outcome in this instance as we didn’t get too much hot money in the stock. All that buying has exited immediately IMO which creates a great opportunity for those of us with patient capital.
ARDS is a massive market that has had very little pharmaceutical progress in the last 40 years. COVID will accelerate the drug development but ARDS does not require the virus to be a company making discovery.
One of the greatest value arbitrage opportunities exists in biotech because the average punter either can’t be bothered understanding the science or doesn’t have the concentration span to even try. That’s good for us and IHL.
IHL Price at posting:
5.9¢ Sentiment: Buy Disclosure: Held
